node cells (80,000-625 cells/well) were expanded in the presence of 106 syngeneic irradiated spleen cells and 10 #M SpWMb in flat-bottom, 96-well microtiter plates (Linbro, McLean, VA). 20 U/ml of rIL-2 were added at the beginning of the culture period. Microcultures were fed on day 7. On day 12, the cultures were washed three times and restimulated with fresh feeder cells and SpWMb in the absence of exogenous IL-2. Proliferation was assessed byyH]thymidine incorporation after 72 h. Individual cultures were scored positive when [ H]thymidine incorporation exceeded background levels of control cultures by more than three standard deviations. Data were analyzed by Poisson analysis.
ResuLts and Discussion
Treatment with rIL-2 In Vivo Induced Polyclonal IgM Production. To study the role of rIL-2 in a humoral immune response in vivo, mice were treated with rIL-2 for 3 d after immunization with a soluble antigen. Conventional immunization with soluble SpWMb induced the production of IgM antibodies in the primary response and a mixture of IgM and IgG antibodies in the secondary response (Fig. 1) . When SpWMb was given in CFA, the animals produced IgM and IgG anti-SpWMb antibodies in the primary response and showed increased IgG concentrations after secondary antigen challenge (Fig. 1) . Treatment with three daily doses of 5,000 U rIL-2 injected after immunization caused a 3-10-fold increase in the IgM titers to both antigens. Administration of rIL-2 did not influence 1gG production in any of the experimental groups. Surprisingly, mice treated with r|L-2 alone without exogenous antigen also developed elevated titers of antibodies specific to SpWMb (Fig. 1 a) . Such antibodies induced by the rlL-2 injection were exclusively IgM. The second series of rIL-2 injections on days 15, 16, and 17 was again followed by the production of anti-SpWMb IgM antibodies. To exclude a possible nonspecific effect and to analyze the spectrum of IgM antibodies produced in rIL-2-treated mice, sera from rIL-2-treated mice were tested for their anti-KLH reactivity. All mice that received high doses of rIL-2 produced IgM (but not IgG) antibodies against KLH (Fig. 2) . To analyze the specificity of the rIL-2-induced IgM antibodies, we absorbed pooled sera from five BALB/c mice on SpWMb-coupled plates. After repeated absorptions, the antibodies binding to SpWMb were removed without altering the titer of anti-KLH antibodies (data not shown). This result showed that antibodies with different specificities were present in sera of mice treated with rIL-2, and suggested the possibility that rIL-2 induced a polyclonai stimulation of IgM antibody production. Similar effects (i.e., three-to sixfold-increased antibody responses) were obtained when BALB/c mice were immunized with KLH and when A/J mice were given (H,G)-A-L followed by rlL-2 (data not presented).
Treatment with rlL-2 In Vivo Induced Polyclonal T Cell Activation.
It is conceivable that rIL-2 primarily expanded the pool of antigen-specific T cells, and thus secondarily affected B cell function. To analyze the possibility of a direct effect of injected rIL-2 on T cells, a limiting-dilution system was established that allowed the estimation of precursor frequencies of SpWMb-specific proliferative T cells. In naive DBA/2 mice, 1 in 40,120 lymph node cells proliferated in response to SpWMB (Fig. 3) . After a single immunization with SpWMb, the frequency of proliferative T cell precursors in regional draining lymph nodes increased ~3.5-fold to 1 in 11,625. Lymph nodes of rIL-2-treated animals contained as many SpWMb-specific proliferative T cells as did animals immunized with SpWMb (1 in 12,410). Injection of rIL-2 in vivo in addition to SpWMb, further increased SpWMb-specific proliferative T cells to a frequency of 1 in 4,530.
Immunization with Specific Antigen Induced a Polyclonal IgM Response. Activation of T lymphocytes by specific antigen is generally accompanied by the release of endogenous IL-2. To test the hypothesis that exogenous rIL-2 might mimic a physiological effect of locally released IL-2 we measured antibody titers against the unrelated antigen KLH in the sera of SpWMb immunized mice. Similar to results seen in rIL-2 treated mice, IgM antibodies specific for KLH were found after immunization with SpWMb (Fig. 2) .
Potential Mechanisms of Action of rlL-2 In Vivo. In contrast to recently published data (8), we did not find an effect of rIL-2 on IgG antibody production, nor could we overcome Ir gene-controlled low responsiveness. Our observation that the injection of rIL-2 enhanced the production of antigen-specific antibodies might be explained by a direct effect of rlL-2 on the antigen-specific helper T cells. In our analysis of the T cell repertoire, similar frequencies of T cells responded to SpWMb in immunized and unimmunized rIL-2-treated mice. However, the frequency of SpWMb-reactive T cells after administration of both antigen and IL-2 seemed additive (Fig. 3) . Not only did we see this additive effect at the level of T cell precursor frequencies, but IgM antibodies were additionally enhanced in the presence of IL-2 and antigen compared with either antigen or IL-2 alone (Fig. 1) . The implications of these findings are interesting but currently unexplained.
In studies reported in this paper, the effect of exogenous rIL-2 was restricted to an augmentation of IgM production suggesting that the adjuvant-like effect of rIL-2 is isotype selective. A random expansion of antigen-specific helper T cells might be expected to affect both ]gM and IgG responses. However, as reported from our laboratory and elsewhere, helper T cells have two independent pathways of help (7, 9) , and it is possible that rIL-2 activates only the IgM pathway. Alternatively, there might be a direct effect of high doses of rIL-2 in vivo on lgM-producing B cells. B cell responses are regulated by a number of antigen-nonspecific, genetically unrestricted factors derived from T cells (10). Recently (6), the expression of functional IL-2 receptors on activated B cells was shown using anti-Tac, an mAb against the IL-2 receptor molecule and by binding studies with purified radiolabelled IL-2. High doses of rIL-2 showed definite activity as a differentiation factor in IgM synthesis in vitro (11). Other studies (12) have suggested that IL-2 can function in B cell proliferation induction. The concentrations necessary for the B cell differentiative activity in vitro (100 U/ ml) or for B cell proliferation were probably achieved transiently in our model. In our immunization protocol, the administration of exogenous rIL-2 might provide a proliferative signal and/or a terminal differentiation signal to selected B cells resulting in a high rate of IgM synthesis and secretion.
To test the hypothesis that rI L-2 may have a direct effect on B cells, we studied rIL-2 in three different T cell-depleted (deficient) animal models: the nude mouse, the thymectomized, irradiated, bone marrow-reconstituted mouse (ATxBm), and the T helper cell-depleted mouse (by repeated treatment in vivo with anti-L3T4 mAb). Swiss nude mice, which received a total dose of 45,000 U rIL-2 over 3 d produced equivalent amounts of IgM anti-SpWMb compared to Swiss nu/+ controls (data not shown). The nude mouse may be not an optimal system to study T cell-independent effects. Residual T cell precursors might differentiate without thymic influence, especially in the presence of exogenous IL-2. Additional evidence that rIL-2 may directly stimulate B cells came from a second model. Treatment of mice with 600 ug mAb against L3T4 completely inhibited their primary response to antigen (13), however, such L3T4-depleted mice produced normal levels of IgM in response to the administration of rIL-2. In contrast, ATxBm mice failed to produce antibody in response to rIL-2 administration (data not presented).
Though we cannot exclude the possibility that rIL-2 acts on T cells and secondarily induces polyclonal IgM secretion, the selective effect of rIL-2 on the secretion of IgM antibodies might reflect the direct activation of a subset of B cells. Ly-1 B cells have been described (14) IL-2 production and release into the local microenvironment seems to be a constant feature of every immune response. We do not know if such local IL-2 concentrations are comparable to the concentrations achieved by the administration of exogenous rIL-2 in this study. As the administration of rIL-2 alone triggered a humoral immune response against unrelated antigens, immunization with a specific antigen resulting in IL-2 production might be accompanied by a polyclonal IgM response. Indeed, we found elevated IgM titers against KLH in mice that had been immunized with SpWMb (Fig. 2) .
The observed enhancement of the IgM response may be of therapeutic relevance. Recent observations in our laboratory suggests that pretreatment with rIL-2 can increase the survival of mice subsequently (1 wk later) challenged with an LDs0 dose of E. coli. (Weyand, C., J. Goronzy, P. O'Hanley, and C. G. Fathman, manuscript in preparation).
Summary
We studied the potential immunoenhancing effects of high doses of rlL-2 on murine T and B cell functions in vivo. Injection of rIL-2 caused a threefold or more increase in the frequencies of antigen-specific proliferative T cells, suggesting that rIL-2 initiated a polyclonal T cell response. In primary and secondary humoral immune responses, administration of rIL-2 in vivo selectively enhanced the production of IgM antibodies, whereas the IgG response was unaffected. Coadministration of rIL-2 with antigen failed to induce an isotype switch from IgM to IgG in genetically low-responding mice. Interestingly, in mice treated with rIL-2 alone (in the absence of exogenous antigen), polyclonal IgM production was induced. Polyclonal IgM production of lesser magnitude was found when mice were immunized with specific antigen in the absence of exogenous rIL-2, suggesting that local IL-2 concentrations in a primary immune response might be sufficient to elicit a polyclonal IgM response.
